The Isosorbide Mononitrate Glucose Injection Market is expected to experience steady growth as healthcare systems address increasing cardiovascular treatment needs. The market is projected to expand from USD 800 million in 2024 to USD 1.5 billion by 2035, reflecting a 5.9% CAGR between 2025 and 2035.

Growing cardiovascular disease prevalence remains a key market driver. Demand for effective therapies is being reinforced by demographic changes, particularly the expansion of older populations that require more frequent cardiovascular care and pharmaceutical intervention.

Administration route is another important area of market segmentation. Intravenous products are expected to remain prominent because of their rapid action and relevance in hospital-based treatment, while other administration routes can provide flexibility for different clinical settings and patient requirements.

Regional healthcare investment will influence future market development. North America is expected to lead, followed by established European markets, while Asia Pacific is positioned as a high-potential region because of expanding healthcare access and evolving medical needs.

Future opportunities could emerge from smart drug-delivery technologies, improved formulations, and stronger pharmaceutical manufacturing partnerships. AI-based analysis and patient-focused treatment strategies may further support innovation, helping manufacturers improve dosing approaches and strengthen the overall value of injectable cardiovascular therapies.